venetoclax

Overview

Venetoclax is a small-molecule anticancer drug that inhibits B-cell lymphoma 2 (BCL-2), a key anti-apoptotic protein encoded by the B-cell lymphoma 2 gene. By blocking BCL-2, venetoclax promotes programmed cell death in cells that depend on BCL-2 for survival, particularly malignant hematologic cells. It is therefore classified among BH3-mimetic agents, a group of compounds designed to mimic pro-apoptotic signaling and shift the balance toward apoptosis.

Clinically, venetoclax has become an important targeted therapy in hematologic malignancies, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). In recent research, it has been studied both as a single targeted component and in combination with other agents such as azacitidine, acalabrutinib, obinutuzumab, bendamustine-rituximab, and high-dose cytarabine plus mitoxantrone. These studies reflect its central role in fixed-duration targeted regimens and in combination strategies aimed at improving depth and durability of response while limiting reliance on conventional chemotherapy.

Focus of Latest Publications

Recent studies examined venetoclax combined with hypomethylating agents (HMAs) as standard therapy for elderly and unfit patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A fixed-time treatment approach involving six months of HMA-venetoclax therapy demonstrated that selected patients achieving complete remission could discontinue treatment without adverse impact on relapse-free or overall survival. Among the seven patients in this cohort, five showed clearance of somatic mutations below 1% with resolution of cytogenetic abnormalities, and six maintained continuous remission for 7–50 months. To address suboptimal responses, researchers evaluated adding rosuvastatin to venetoclax-azacitidine, achieving composite complete remission (CRc) rates of 72.2% and CR rates of 55.5%, with evidence that rosuvastatin reduces T-cell exhaustion. Integrated ex vivo drug sensitivity testing combined with genetic mutation analysis identified predictive biomarkers: DNMT3A mutations were associated with greater resistance to venetoclax, whereas CEBPA mutations correlated with increased sensitivity, providing a framework for precision treatment selection. Studies of serial 28-day venetoclax cycles administered preremission and postremission in newly diagnosed unfit patients reported overall response rates of 64.9%, demonstrating tolerability despite higher early hematologic myelosuppression.

Venetoclax was evaluated in combination with novel cellular therapies and small molecules across broader AML populations and other hematologic malignancies. Low-dose venetoclax combined with CD123 CAR-T cells enhanced cytotoxicity in myeloid neoplasms, with pretreatment of CAR-T cells with venetoclax generating V-CD123 CAR-T cells that significantly improved killing efficiency at low effector-to-target ratios through metabolic reprogramming. In pediatric acute myeloid leukemia with KMT2A rearrangements, venetoclax combined with IACS-010759, a mitochondrial complex I inhibitor, reduced disease progression in both disease-onset and relapse models. For salvage therapy in relapsed or refractory AML, venetoclax was combined with high-dose cytarabine and mitoxantrone to evaluate safety and activity. In T-cell acute lymphoblastic leukemia (T-ALL), early T-cell precursor (ETP) ALL demonstrated sensitivity to venetoclax, with synergistic effects observed when combined with natural killer cell-mediated immunotherapy. For AML developing from prior myeloproliferative neoplasms, venetoclax represented a novel targeted therapy to address historically poor outcomes.

Fixed-duration venetoclax combinations became standard first-line treatment in chronic lymphocytic leukemia (CLL). The CLL13/GAIA phase III trial evaluated three time-limited regimens—venetoclax-rituximab, venetoclax-obinutuzumab, and venetoclax-obinutuzumab-ibrutinib—compared to chemoimmunotherapy in fit patients without TP53 aberrations. Five-year progression-free survival (PFS) rates were 81.3% for venetoclax-obinutuzumab-ibrutinib, 69.8% for venetoclax-obinutuzumab, 57.4% for venetoclax-rituximab, and 50.7% for chemoimmunotherapy. Patients receiving venetoclax combinations reported rapid and significantly greater quality-of-life improvements compared to chemoimmunotherapy, and treatment-free survival exceeded 80% at two years from second-line retreatment. In relapsed or refractory CLL, duvelisib plus venetoclax achieved overall response rates of 91% with median PFS of 46 months and 3-year PFS of 67%, although grade ≥3 neutropenia occurred in 91% of patients. ibrutinib combined with venetoclax in relapsed or refractory CLL achieved complete remission or CR with incomplete count recovery (CRi) rates of 67%, with 61% achieving undetectable bone marrow minimal residual disease and an estimated 7-year PFS of 63.3%.

Pharmacokinetic studies of venetoclax in combination with triazole antifungal agents (posaconazole or voriconazole) for invasive fungal infection prophylaxis in myeloid neoplasms found that reducing venetoclax to 100 mg maintained therapeutic drug exposure while mitigating infection risk, without increasing severe hematological or gastrointestinal adverse events. Treatment-related cardiovascular adverse events were identified as a safety consideration requiring monitoring in AML patients receiving venetoclax-based therapy. Beyond hematologic malignancies, a phase Ib trial combining enzalutamide with venetoclax in castration-resistant prostate cancer demonstrated reduced circulating tumor cells in responding patients, supporting BCL-2 as a therapeutic vulnerability in androgen receptor-positive disease. Sonrotoclax, a second-generation BCL-2 inhibitor with greater than 10-fold greater potency than venetoclax, was approved as the first BCL-2 inhibitor for relapsed or refractory mantle cell lymphoma and is undergoing head-to-head comparison with venetoclax in phase III CLL trials, potentially reshaping the treatment landscape for BCL-2-driven lymphoid malignancies.

Key Publications

• NEWJun Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. (Annals of hematology, 2026, PMID 42277354): "We investigated the effects of Venetoclax (Ven) on the proliferation, subset distribution, and cytotoxic activity of CD123 CAR-T cells."
• May Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia. (Functional & integrative genomics, 2026, PMID 42209825): "Sensitivity to 10 commonly used chemotherapeutic agents (including venetoclax) and 20 combination regimens was assessed."
• May Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax - a case series. (Annals of hematology, 2026, PMID 42171770): "Standard therapy for elderly patients with acute myeloid leukemia (AML) consists of hypomethylating agents (HMAs) combined with venetoclax (VEN), administered long term until disease progression."
• Jul First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma. (Cancer discovery, 2026, PMID 42166034): "The drug, which binds BCL-2 with more than 10-fold greater potency than venetoclax and may carry a cleaner platelet toxicity profile, is now being tested head-to-head against venetoclax in multiple phase III chronic lymphocytic leukemia trials that could reshape the treatment landscape for that disease as well."
• Jun Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. (Cancer, 2026, PMID 42159161): "Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial."
• May A venetoclax-cytarabine-based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia. (Cancer, 2026, PMID 42118656): "suggesting their potential benefit when combined with venetoclax and cytarabine in de novo AML patients."
• May Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia. (Journal of the American Heart Association, 2026, PMID 42089196): "Venetoclax, a potent B-cell leukemia/lymphoma-2 inhibitor, is an antineoplastic agent used in various hematologic malignancies, including acute myeloid leukemia (AML)."
• May Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion. (Cancer immunology, immunotherapy : CII, 2026, PMID 42082682): "A multicenter phase II clinical trial (ChiCTR 2500111931) was conducted to evaluate the efficacy and safety of adding rosuvastatin to venetoclax and azacitidine (venetoclax-azacitidine) in older/unfit AML patients."
• May Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. (Signal transduction and targeted therapy, 2026, PMID 42067541): "A Phase Ib clinical trial (NCT03751436) combining enzalutamide and BCL-2 inhibitor venetoclax demonstrated reduced circulating tumor cells in responding patients."
• May Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States. (Cancer, 2026, PMID 42033416): "The treatment of AML has been revolutionized in recent years with the introduction of novel targeted therapies including the BCL2 inhibitor venetoclax (VEN)."